Date: January 27, 2018 @ 1:30 pm – @ 4:00 pm
Location: Hanqi Investments (1633 Bayshore Highway, Suite 280, Burlingame, CA 94010)

Novel antibody platforms and applications

Please register online. Online registration is free. Onsite registration is $10.

1:30 - 2:00PM check-in, onsite registration and networking

2:00PM - 4:00PM


1. Yiyuan Yin, PhD, Scientist at NGM Biopharmaceuticals.

Yiyuan Yin has over 10 years of experience in antibody and protein engineering. Her expertise covers broad aspects of biologics discovery, and has published numerous works on bispecific antibodies, computational designs, antibody display technologies etc. Yiyuan is currently a Scientist at NGM Biopharmaceuticals, where she has spearheaded many technology development programs, and has advanced multiple pipeline projects with her state-of-the-art skills. Prior to that, she did her postdoc research at Genentech with Dr. Paul Carter, who is a renowned pioneer in the field of antibody engineering. Yiyuan received her B.S. from Fudan University in Shanghai, China. During her PhD training at the University of Maryland, she conducted researches in structural biology, biophysics and protein engineering with a focus on immune receptors.

Talk title: Novel antibody platforms and their therapeutic potentials


2. Jianlong Luo, PhD, Associate Professor at UCSF

As a faculty member (Associate Professor) at UCSF, Dr. Jianlong Lou was systematically trained in China, Italy and USA in the life science and medical related fields. As principal investigator or co-investigator or key personal in the research teams or supporting technical expert together with Dr. Andrew Bradbury and Dr. James D Marks, Dr. Lou has been doing antibody engineering over three decades, engaged in at least 35 research grants with total funding over $100 million from different governmental agencies or industrial partners in the past 25 years. Dr. Lou has applied animal immunization, hybridoma, phage display, yeast display, mammalian cell antibody production, computer-based antibody humanization and many other modern molecular engineering technologies for antibody optimization. He has authored or co-authored three scientific books and over 50 peer-reviewed research papers, with thousands of worldwide SCI citations. He is also the active reviewer for papers in five international journals in the life or medical science field. Dr. Lou is the co-inventor for 6 granted and 7 pending US and worldwide patents since 2006. Most of the awarded patents were out-licensed to industry partners, and one of the license deal to a big pharmaceutical partner was the largest (dollar amount) license deal UCSF ever signed till 2012 and also ranked in the top 1% of all license deals from any academic institute to industry. Several human antibody drugs from his invention are in different stages of clinical trial in USA. 

Talk title: The Beauty of Synergy: A tri-epitope molecular captures the potency of three mAb combination in BoNT Neutralization. 

Online Registration – $0 (USD)